Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The landscape of gain and loss of function mutations in melanoma

ABSTRACT: Melanoma is a common and aggressive cancer, with a rising incidence in most developed countries. Major discoveries in melanoma biology have been rapidly translated, allowing cures for some late-stage patients. Despite these advances, incomplete knowledge of genes and pathways that are gained or lost during melanogenesis prohibits cures for many patients. To identify gain of function and loss of function drivers of melanoma, we established a multi-omics cohort of melanoma patient-derived xenografts (melPDomiX). By linking mutations with gene and protein expression, we characterize gain or loss of function of specific melanoma drivers in treatment refractory tumor models. We use multi-omics integration and structural-context representation to distinguish gain from loss of function variants, revealing new candidate melanoma genes and targets. This study provides a comprehensive resource of tumor models with the genetic, molecular and structural features of gain and loss of function melanoma drivers, allowing future development of better therapeutics for this devastating and heterogenous malignancy.

ORGANISM(S): Homo sapiens

PROVIDER: GSE298502 | GEO | 2026/05/17

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

The landscape of gain and loss of function mutations in melanoma [RNA-seq]

Project description:Melanoma is a common and aggressive cancer, with a rising incidence in most developed countries. Major discoveries in melanoma biology have been rapidly translated, allowing cures for some late-stage patients. Despite these advances, incomplete knowledge of genes and pathways that are gained or lost during melanogenesis prohibits cures for many patients. To identify gain of function and loss of function drivers of melanoma, we established a multi-omics cohort of melanoma patient-derived xenografts (melPDomiX). By linking mutations with gene and protein expression, we characterize gain or loss of function of specific melanoma drivers in treatment refractory tumor models. We use multi-omics integration and structural-context representation to distinguish gain from loss of function variants, revealing new candidate melanoma genes and targets. This study provides a comprehensive resource of tumor models with the genetic, molecular and structural features of gain and loss of function melanoma drivers, allowing future development of better therapeutics for this devastating and heterogenous malignancy.

2026-05-17 | GSE297199 | GEO

The landscape of gain and loss of function mutations in melanoma [WES]

2026-05-17 | GSE297200 | GEO

Parental MeWo and highly metastatic LM2 human melanoma cell line derivatives with or without miR-199a or miR-1908

Project description:Human melanoma MeWo cells and their respective LM2 metastatic derivatives, generated through in vivo selection, were transcriptomically profiled in the context of miR-199a and miR-1908 gain- and loss-of-function in order to identify putative target genes for these miRNAs, MeWo cells and their respective LM2 metastatic derivatives in the context of miR-199a and miR-1908 gain- and loss-of-function

2013-02-10 | E-GEOD-35668 | biostudies-arrayexpress

Medicago truncatula

Project description:MtDASH Gain and loss of function mutants

| PRJNA248946 | ENA

Effect of MDK expressing Melanoma cells conditioned media in Human LEC

Project description:Gene expression analysis in hLECs treated with gain of function or loss of function of MDK in human melanoma cells.

2017-06-27 | GSE94549 | GEO

Identification of a Midkine-associated gene expression profile in melanoma cells

Project description:We performed gain-of-function (GoF) and loss-of-function (LoF) analyses of Midkine in melanoma cells by RNA-seq.

2020-10-15 | GSE131203 | GEO

Gene expression profiling of melanoma cell lines (carrying NF1 loss-of-function) treated with DMSO (vehicle), MTX-216, MTX-211, trametinib, the combination of MTX-216 and trametinib, or pictilisib

Project description:In this study, we identified a multi-kinase inhibitor MTX-216 to be efficacious in blocking NF1 loss-of-function melanoma cells. To identify the mechansisms of action of MTX-216, we treated NF1 loss-of-function melanoma cell lines with MTX-216, MTX-211 (the structural analogue of MTX-216 that has no effect on melanoma cells) as well as commericial kinase inhibitors, trametinib and pictilisib, and compared their gene expression profiles.

2022-09-20 | GSE213588 | GEO

Gain-of-function CRISPR screens identify tumor driver genes conferring melanoma cell plasticity and therapy-resistance

Project description:Most genetic events that drive melanoma development and resistance to targeted therapy have been uncovered. In contrast, and despite their increasingly recognized contribution, little is known about the non-genetic mechanisms that drive these processes. Here, we performed in vivo gain-of-function CRISPR screens and identified SMAD3, BIRC3 and SLC9A5 as key drivers of BRAFi-resistance and the tumor growth capability of persister cells. We show that their expression levels increase during acquisition of BRAFi-resistance, and remain high in persister cells and during relapse. Critically, chemical inhibition of SMAD3 or BIRC3 efficiently abrogates melanoma tumor growth and persister cells proliferation. Genetic inhibition of these targets efficiently restored the sensitivity of persister cells to BRAFi. Our work expands our understanding of the biology of persister cells and highlight novel drug vulnerabilities that can be exploited to develop long-lasting anti-melanoma therapies.

2021-02-03 | E-MTAB-8595 | biostudies-arrayexpress

Canine pimary osteosarcoma tissues vs. matched lung metastases

Project description:Osteosarcomas (OS) have highly chaotic genomes, yet their cancer drivers are poorly defined. Given that cancer genes are conserved among mammals, cross-species genomics of naturally arising cancers opens a powerful approach to identifying oncogenic drivers to broaden the therapeutic opportunities for aggressive cancers. Here, we utilized a dog-to-human cross-species genomics combined with gain- and loss-of-function analysis to uncover novel OS driver genes.

2021-08-03 | GSE118130 | GEO

Arabidopsis thaliana

Project description:RNAseq analysis of NGATHA loss and gain of function alleles

| PRJNA242915 | ENA